MedTrace Logo

Aldosterone Antagonism in Diastolic Heart Failure

NCT00108251 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2011-09-08

No results posted yet for this study

Summary

The primary purpose of this study is to determine whether eplerenone has a beneficial effect on improving exercise ability in patients with diastolic heart failure.

Conditions

  • Congestive Heart Failure
  • Diastole

Interventions

DRUG

Eplerenone

aldosterone receptor blocker

DRUG

Placebo

matching placebo

Sponsors & Collaborators

Principal Investigators

  • Anita Deswal, MD MPH MBBS · Michael E. DeBakey VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2007-09-30
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00108251 on ClinicalTrials.gov